Seeking Alpha

Joe Springer's  Instablog

Joe Springer
Send Message
We love the royal "we". Email joespringernews@gmail.com to be added to our free newsletter. Check out our record picking stocks: http://seekingalpha.com/article/1896981-6-doubles-in-a-row-and-2014s-top-pick Please follow us on Twitter and subscribe to our Youtube channel:... More
  • Merck Looks Poised For MannKind 11 comments
    Oct 28, 2013 2:10 PM | about stocks: MNKD, MRK

    Back in the Spring I opined that I thought Merck would partner with MannKind after data came back from the Affinitty trials. I still think it will happen - Merck issued a press release saying they are cutting back on R&D and refocusing. From the October 1st press release:

    • The company will increase its focus on the key therapeutic areas that meet unmet medical needs, provide the best opportunities for the business and deliver the greatest value for customers - diabetes, acute hospital care, vaccines and oncology.

    Then on Merck's Q3 conference call this morning prepared statements included:

    "As we think about our business going forward, we are focused on balancing the short term and the long term by resourcing the key internal programs to deliver our pipeline, including potential game-changers like anti-PD1, while also augmenting our pipeline with even greater emphasis on external opportunities."

    and

    "we remain ready to bolster the pipeline with external innovation at any time"

    In response to a question:

    Roger Perlmutter - President, Merck Research Laboratories

    "With respect to our programs, we have been looking at a variety of different ways to assist in the therapy of patients with diabetes. We haven't disclosed any information about how we might move forward in that area, so I really don't have any comments about that."

    Things are not going well for Merck. They have plenty of money and credit but they are under pressure and need to make something happen. They repeatedly brought up their patents expiring and their lead diabetes drug Januvia actually shrank in sales last quarter - while diabetes remains one of the fastest growing diseases in the world.

    I think Merck and MannKind will partner up.

    ...also I am working on an in-depth article on a new stock, email joespringernews@gmail.com to be added to my free newsletter.

    Disclosure: I am long MNKD.

    Themes: Diabetes, Januvia Stocks: MNKD, MRK
Back To Joe Springer's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (11)
Track new comments
  • goinglong2020
    , contributor
    Comments (140) | Send Message
     
    Looking forward to your newest article Joe!
    28 Oct 2013, 02:34 PM Reply Like
  • Joe Springer
    , contributor
    Comments (2303) | Send Message
     
    Author’s reply » Thank you GL2020!
    28 Oct 2013, 03:18 PM Reply Like
  • joe kelly
    , contributor
    Comments (1777) | Send Message
     
    Merck sounds like TEVA. On a money saving binge. I've been at places that tied that and it never worked out. Drove away customers.
    Plus, I like MNKD as well but, and my wife is constantly frustrated by my lack of sensitivity, Mr. Mann isn't getting any younger.Someone like he, or maybe Dr. Frost of OPKO fame goes to the great beyond that spells doom for their companies.

     

    Please correct me if I'm wrong Joe. Dig your picks and logic behind them. Got a boatload of IMUC.
    28 Oct 2013, 03:04 PM Reply Like
  • Joe Springer
    , contributor
    Comments (2303) | Send Message
     
    Author’s reply » Thanks Joe, that point about succession planning has been brought up a lot, and rightly so given his age, but succession plans are in place, his daughter is set to take over if need be, and some feel that value might be unlocked if she did take the reigns.
    28 Oct 2013, 03:17 PM Reply Like
  • OverSouled
    , contributor
    Comments (125) | Send Message
     
    If that happens will the company be renamed Womannkind?
    28 Oct 2013, 03:32 PM Reply Like
  • Joe Springer
    , contributor
    Comments (2303) | Send Message
     
    Author’s reply » Yes, of course.

     

    : )
    28 Oct 2013, 03:35 PM Reply Like
  • drew111
    , contributor
    Comments (444) | Send Message
     
    Joe, I was watching CNBC earlier today when they brought up Merk. My first thought was that Mannkind would fit into the Merk puzzle either as a partner or merger/buy out. Nice to see that I am not the only one.
    28 Oct 2013, 04:43 PM Reply Like
  • Joe Springer
    , contributor
    Comments (2303) | Send Message
     
    Author’s reply » Nice to have your company Drew!
    28 Oct 2013, 07:28 PM Reply Like
  • opc3
    , contributor
    Comments (3) | Send Message
     
    Joe, I've detailed some other interesting relationships between MRK and MNKD that you may not have been aware of. They have always been my odds-on pick. I noted those relationships in a post on Mannkind Central. (mannkind.freeforums.n...

     

    Hope to see you over there.
    28 Oct 2013, 06:44 PM Reply Like
  • Joe Springer
    , contributor
    Comments (2303) | Send Message
     
    Author’s reply » Thank you opc3, I just registered - I must say I am impressed! I thought it was just a message board but you have all the transcripts, press releases, links, what a great resource!
    28 Oct 2013, 07:31 PM Reply Like
  • sheldond
    , contributor
    Comments (1136) | Send Message
     
    That would be nice with my current position! I am excited about MNKD in the future.

     

    Best,

     

    D
    28 Oct 2013, 09:55 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
  1. Fire Away (135 Comments)
  2. I Am You See (101 Comments)
  3. What Is Tonix Worth? (89 Comments)
  4. Hooked On Tonix (64 Comments)
  5. Seattle Super-Tonix (53 Comments)
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.